Product
Patsnap Eureka
For R&D, Patsnap Eureka makes reading and utilizing patents & technical documents easy.
Patsnap Eureka AIR
Designed for self-driven R&D workflows. Generate viable solutions, solve complex R&D challenges, empower your innovation with AI.
Patsnap Eureka Materials
Designed for material experts only. Revolutionize your material R&D, from search, analyze, to developing new materials.
Feature
TechResearch
Generate reliable direction feasibility study reports for your R&D in just a few steps.
TechSeek
Discover and master advanced knowledge NOW. Basics, ideas, possibilities, all at once.
TechMind
As an expert in R&D Theories, TechMind can generates customized viable solutions instantly.
TechRisk
Analyze your overall solution with one click, know your potential R&D risks in advance.
TechMonitor
Get weekly tech updates, stay abreast of the latest tech innovations and key insights.
Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
33 results about "Cftr modulator" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
CFTR modulators are a specialized group of CF therapies designed to address the underlying cause of CF according to the specific defect in the CFTR protein. There are three main types of CFTR modulators: A normal CFTR protein sits on the cell surface and acts as a gated passageway for the transport of chloride ions across cell membranes.
Indole derivatives as CFTR modulators
Compounds of the present invention and pharmaceutically acceptable compositions thereof, are useful as modulators of ATP-Binding Cassette (“ABC”) transporters or fragments thereof, including Cystic Fibrosis Transmembrane Conductance Regulator (“CFTR”). The present invention also relates to methods of treating ABC transporter mediated diseases using compounds of the present invention.
Owner:VERTEX PHARMA INC
Pyridyl derivatives as cftr modulators
The present invention relates to modulators of ATP-Binding Cassette (“ABC”) transporters or fragments thereof, including Cystic Fibrosis Transmembrane Conductance Regulator (“CFTR”), compositions thereof, and methods therewith. The present invention also relates to methods of treating ABC transporter mediated diseases using such modulators.
Owner:VERTEX PHARMA INC
Azaindole derivatives as cftr modulators
The present invention relates to modulators of ATP-Binding Cassette (“ABC”) transporters or fragments thereof, including Cystic Fibrosis Transmembrane Conductance Regulator (“CFTR”), compositions thereof, and methods therewith. The present invention also relates to methods of treating ABC transporter mediated diseases using such modulators.
Owner:VERTEX PHARMA INC
Indole derivatives as CFTR modulators
Compounds of the present invention and pharmaceutically acceptable compositions thereof, are useful as modulators of ATP-Binding Cassette (“ABC”) transporters or fragments thereof, including Cystic Fibrosis Transmembrane Conductance Regulator (“CFTR”). The present invention also relates to methods of treating ABC transporter mediated diseases using compounds of the present invention.
Owner:VERTEX PHARMA INC
Prodrugs of modulators of ABC transporters
InactiveUS20090105272A1Good water solubilityImprove bioavailabilityAntibacterial agentsCompound screeningDiseaseStereochemistry
The present invention relates to prodrugs of modulators of ABC transporters, particularly, CFTR modulators, compositions thereof, and methods therewith. The present invention also relates to methods of treating ABC transporter mediated diseases using such modulators.
Owner:VERTEX PHARMA INC
Heteroaryl derivatives as cftr modulators
The present invention relates to modulators of ATP-Binding Cassette (“ABC”) transporters or fragments thereof, including Cystic Fibrosis Transmembrane Conductance Regulator (“CFTR”), compositions thereof, and methods therewith. The present invention also relates to methods of treating ABC transporter mediated diseases using such modulators.
Owner:VERTEX PHARMA INC
Modulators of Cystic Fibrosis Transmembrane Conductance Regulator
The present invention relates to modulators of cystic fibrosis transmembrane conductance regulator (“CFTR”), compositions thereof, and methods therewith. The present invention also relates to pharmaceutical compositions comprising a compound of Formula I with one or both of a Compound of Formula II and / or a Compound of Formula III. Further, the present invention relates to methods of treating CFTR mediated diseases, particularly cystic fibrosis, using modulators of CFTR, and compositions and combinations thereof.
Owner:VERTEX PHARMA INC
Pyridyl derivatives as CFTR modulators
The present invention relates to modulators of ATP-Binding Cassette (“ABC”) transporters or fragments thereof, including Cystic Fibrosis Transmembrane Conductance Regulator (“CFTR”), compositions thereof, and methods therewith. The present invention also relates to methods of treating ABC transporter mediated diseases using such modulators.
Owner:VERTEX PHARMA INC
Heteroaryl derivatives as CFTR modulators
The present invention relates to modulators of ATP-Binding Cassette (“ABC”) transporters or fragments thereof, including Cystic Fibrosis Transmembrane Conductance Regulator (“CFTR”), compositions thereof, and methods therewith. The present invention also relates to methods of treating ABC transporter mediated diseases using such modulators.
Owner:VERTEX PHARMA INC
Modulators of cystic fibrosis transmembrane conductance regulator
The present invention relates to modulators of ATP-Binding Cassette (“ABC”) transporters or fragments thereof, including Cystic Fibrosis Transmembrane Conductance Regulator, compositions thereof, and methods therewith. The present invention also relates to methods of treating diseases using such CFTR modulators.
Owner:VERTEX PHARMA INC
Modulators of cystic fibrosis transmembrane conductance regulator
The present invention relates to modulators of cystic fibrosis transmembrane conductance regulator (“CFTR”), compositions thereof, and methods therewith. The present invention also relates to methods of treating diseases using modulators of CFTR.
Owner:VERTEX PHARMA INC
Modulators of cystic fibrosis transmembrane conductance regulator
The present invention relates to modulators of ATP-Binding Cassette (“ABC”) transporters or fragments thereof, including Cystic Fibrosis Transmembrane Conductance Regulator, compositions thereof, and methods therewith. The present invention also relates to methods of treating diseases using such CFTR modulators.
Owner:VERTEX PHARMA INC
Modulators of cystic fibrosis transmembrane conductance regulator
The present invention relates to modulators of cystic fibrosis transmembrane conductance regulator (“CFTR”), compositions thereof, and methods therewith. The present invention also relates to methods of treating diseases using modulators of CFTR.
Owner:VERTEX PHARMA INC
Prodrugs of Modulators of ABC Transporters
InactiveUS20130303484A1Good water solubilityImprove bioavailabilityAntibacterial agentsOrganic active ingredientsDiseaseTranslocator protein
Owner:VERTEX PHARMA INC
Azaindole derivatives as CFTR modulators
The present invention relates to modulators of ATP-Binding Cassette (“ABC”) transporters or fragments thereof, including Cystic Fibrosis Transmembrane Conductance Regulator (“CFTR”), compositions thereof, and methods therewith. The present invention also relates to methods of treating ABC transporter mediated diseases using such modulators.
Owner:VERTEX PHARMA INC
Modulators of cystic fibrosis transmembrane conductance regulator
The present invention relates to compounds of formula IVA, formula IVB, or formula IVC, useful as modulators of ATP-Binding Cassette (“ABC”) transporters or fragments thereof, including Cystic Fibrosis Transmembrane Conductance Regulator, compositions thereof, and methods therewith. The present invention also relates to methods of treating diseases using such CFTR modulators.
Owner:VERTEX PHARMA INC
Modulators of cystic fibrosis transmembrane conductance regulator
The present invention relates to modulators of cystic fibrosis transmembrane conductance regulator (“CFTR”), compositions thereof, and methods therewith. The present invention also relates to methods of treating diseases using modulators of CFTR.
Owner:VERTEX PHARMA INC
Heteroaryl Derivatives as CFTR Modulators
Owner:VERTEX PHARMA INC
Modulators of Cystic Fibrosis Transmembrane Conductance Regulator
The present invention relates to modulators of cystic fibrosis transmembrane conductance regulator (“CFTR”), compositions thereof, and methods therewith. The present invention also relates to methods of treating diseases using modulators of CFTR.
Owner:VERTEX PHARMA INC
Pyrimidine derivatives as cftr modulators
Owner:NUBRIDGE BIOSCI
Pyridine derivatives as cftr modulators
A compound having the structure of Formula II, or a stereoisomer, tautomer, or a pharmaceutically acceptable salt thereof:The compound is useful as CFTR modulator. Further, a method of using the compound and pharmaceutical composition comprising the compound are provided for treating diseases in lungs, pancreas, gastrointestinal system, sinuses, reproductive system, and the sweat glands.
Owner:NUBRIDGE BIOSCI
Azaindole derivatives as cftr modulators
The present invention relates to modulators of ATP-Binding Cassette ('ABC') transporters or fragments thereof, including Cystic Fibrosis Transmembrane Conductance Regulator ('CFTR'), compositions thereof, and methods therewith. The present invention also relates to methods of treating ABC transporter mediated diseases using such modulators.
Owner:VERTEX PHARMA INC
Isothiazole derivatives as CFTR modulators
Owner:NUBRIDGE BIOSCI
Deuterium-modified cftr modulators
InactiveUS20190048020A1Nervous disorderIsotope introduction to heterocyclic compoundsMedicineCftr modulator
This invention relates to novel 4,4,5,5,7,7-hexamethyl-5,7-dihydro-4H-thieno[2,3-c]pyranyl compounds, and pharmaceutically acceptable salts thereof. This invention also provides compositions comprising a compound of this invention and the use of such compositions in methods of treating diseases and conditions that are beneficially treated by administering cystic fibrosis transmembrane conductance regulator (CFTR) modulators.
Owner:VERTEX PHARMA EURO
Deuterated CFTR modulators
ActiveUS10196384B2Isotope introduction to heterocyclic compoundsRespiratory disorderCystic fibrosis lungsCystic fibrosis
Owner:VERTEX PHARMACETICALS (EUROPE) LIMITED
Isothiazole derivatives as CFTR modulators
A compound having the structure of Formula II, or a stereoisomer, tautomer, or a pharmaceutically acceptable salt thereof:The compound is useful as CFTR modulator. Further, a method of using the compound and pharmaceutical composition comprising the compound are provided for treating diseases in lungs, pancreas, gastrointestinal system, sinuses, reproductive system, and the sweat glands.
Owner:NUBRIDGE BIOSCI
Compositions and methods for enhancing ion transporter activity and uses thereof
ActiveUS20210100835A1High activityCell receptors/surface-antigens/surface-determinantsInorganic active ingredientsCation PumpBiochemistry
Methods for enhancing the activity of an ion transporter in a cell and / or treating a channelopathy in a subject based on the administration or use of an effective amount of a fenretinide compound (fenretinide, a fenretinide analog, or a pharmaceutically acceptable salt thereof) and / or zinc are described. The methods are useful for restoring or increasing the cell surface expression of an ion transporter such as the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) that is mutated or defective. The fenretinide compound and / or zinc may be used in combination with ion transporter modulators, e.g., CFTR modulators, to further enhance the cell surface expression and activity of the ion transporter.
Owner:MCGILL UNIV
Use of CFTR Modulators For Treating Cerebrovascular Conditions
PendingUS20210346359A1Increase channel activityHigh activityNervous disorderHeterocyclic compound active ingredientsMedicineBrain vessel
Owner:QANATPHARMA AG
Use of aliginate oligomers and CFTR modulators in treatment of conditions associated with CFTR dysfunction
ActiveUS10751363B2Normalisation of the mucusGood effectRespiratory disorderHeterocyclic compound active ingredientsDiseasePhysiology
A method is for the treatment of a condition in a subject, which arises from or is associated with CFTR dysfunction. The method includes administering to the subject an effective amount of a CFTR modulator together with an effective amount of an alginate oligomer. The condition can be cystic fibrosis (CF), non-compound CFTR gene mutation heterozygosity, abnormal mucus clearance in the respiratory tract and / or breathing difficulties resulting from chronic particulate inhalation, COPD, chronic bronchitis, emphysema, bronchiectasis, asthma or chronic sinusitis, or a complication of any of these.
Owner:ALGIFARMA IPR AS
Cftr regulators and methods of use thereof
InactiveUS20190031630A1Restores tear secretionPrevents corneal epithelial disruptionOrganic active ingredientsSenses disorderOphthalmologyConstipation
Provided herein are compounds that activate CFTR and methods for treating constipation, dry eye disorders or other diseases and disorders.
Owner:RGT UNIV OF CALIFORNIA
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Patsnap Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com